Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Clin Lipidol ; 13(3): 455-467, 2019.
Article in English | MEDLINE | ID: mdl-30928440

ABSTRACT

BACKGROUND: Homozygous familial hypercholesterolemia (HoFH) is a rare, life-threatening inherited disease leading to early-onset atherosclerosis and associated morbidity. Because of its rarity, longitudinal data on the management of HoFH in the real world are lacking, particularly on the impact the condition has on quality of life (QoL), including the impact of the extracorporeal lipid removal procedure apheresis (LA). METHODS: The A-HIT1 study included 88 patients with HoFH aged ≥12 years receiving regular LA in 19 centers in Turkey. Demographic and disease characteristics data were obtained. For patients aged ≥18 years, additional data on psychosocial status were obtained via the SF-36 score, the Hospital Anxiety and Depression Scale, and a HoFH-specific questionnaire. RESULTS: There was no standardized approach to therapy between centers. Mean (±SD) frequency of LA sessions was every 19.9 (±14) days, with only 11.6% receiving LA weekly, and 85% of patients were not willing to increase LA frequency. The most common concerns of patients were disease prognosis (31%), and physical, aesthetic, and psychological problems (27.5%, 15.9%, and 11.6%, respectively). Lower age at diagnosis was associated with better QoL, lower anxiety, improved functioning, and greater emotional well-being compared to later diagnosis. CONCLUSIONS: These findings demonstrate that adult patients with HoFH undergoing LA, experience significant impairment of QoL with an increased risk of depression. From patients' point of view, LA is time-consuming, uncomfortable, and difficult to cope with. The speed of diagnosis and referral has a considerable impact on patient well-being.


Subject(s)
Blood Component Removal , Cholesterol, LDL/blood , Homozygote , Hyperlipoproteinemia Type II/blood , Hyperlipoproteinemia Type II/therapy , Quality of Life , Surveys and Questionnaires , Adolescent , Adult , Female , Humans , Hyperlipoproteinemia Type II/genetics , Male , Middle Aged , Registries , Turkey , Young Adult
2.
Turk J Pediatr ; 61(4): 599-603, 2019.
Article in English | MEDLINE | ID: mdl-31990480

ABSTRACT

Gazeteci-Tekin H, Demir M, Aktan G, Tekgül H, Gökben S. The case of pyridoxine dependent epilepsy misdiagnosed as non-ketotic hyperglycinemia. Turk J Pediatr 2019; 61: 599-603. Pyridoxine-dependent epilepsy (PDE) is a rare but an important condition, since early diagnosis and treatment result in normal or near normal psychomotor development. It is caused by mutations in the Antiquitin (ALDH7A1) gene. Different clinical findings may appear in the deficiency of pyridoxine, which is the cofactor of many enzymes. A wide variety of clinical and laboratory findings can cause confusion during diagnosis. We present a male with neonatal convulsions; structural brain anomaly, hyperglycinemia in CSF/plasma, with ALDH7A1 Compound heterozygote mutation.


Subject(s)
Aldehyde Dehydrogenase/genetics , DNA/genetics , Epilepsy/diagnosis , Hyperglycinemia, Nonketotic/diagnosis , Mutation , Aldehyde Dehydrogenase/metabolism , DNA Mutational Analysis , Diagnosis, Differential , Diagnostic Errors , Epilepsy/genetics , Epilepsy/metabolism , Humans , Infant, Newborn , Male
SELECTION OF CITATIONS
SEARCH DETAIL
...